Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 4 of 4

Full-Text Articles in Medicine and Health Sciences

Oncolog, Volume 48, Number 12, December 2003, Karen Stuyck, Dawn Chalaire, Martha A. Askins Phd, Martha Aschenbrenner Dec 2003

Oncolog, Volume 48, Number 12, December 2003, Karen Stuyck, Dawn Chalaire, Martha A. Askins Phd, Martha Aschenbrenner

OncoLog MD Anderson's Report to Physicians (All issues)

  • On the Move: Efforts Under Way to Improve Outcomes for Patients with Renal Cancer
  • Protocols: Studies Examine Treatments for Renal Cell Carcinoma
  • Art Therapy Helps Children Affected by Cancer Express Their Emotions
  • Children's Art Project Has Been Improving the Lives of Children with Cancer for 30 Years
  • DiaLog: When a Parent Is Sick: Talking to Children about Cancer, by Martha A. Askins, PhD, Division of Pediatrics, and Martha Aschenbrenner, Director, Child Life Services


Patterns Of Breast Recurrence In A Pilot Study Of Brachytherapy Confined To The Lumpectomy Site For Early Breast Cancer With Six Years' Minimum Follow-Up, Francisco Perera, Edward Yu, Jay Engel, Ronald Holliday, Leslie Scott, Frank Chisela, Varagur Venkatesan Nov 2003

Patterns Of Breast Recurrence In A Pilot Study Of Brachytherapy Confined To The Lumpectomy Site For Early Breast Cancer With Six Years' Minimum Follow-Up, Francisco Perera, Edward Yu, Jay Engel, Ronald Holliday, Leslie Scott, Frank Chisela, Varagur Venkatesan

Edward Yu

PURPOSE: In this pilot study of high-dose-rate brachytherapy to the lumpectomy site as the sole radiation, ipsilateral and contralateral breast recurrences are documented with specific attention to the location of recurrence relative to the lumpectomy site. METHODS: Between March 1992 and January 1996, 39 patients with T1 (32 patients) and T2 breast cancers received 37.2 Gy in 10 fractions (b.i.d.) over 1 week prescribed to a volume encompassing the surgical clips. Thirteen received adjuvant tamoxifen, and 4 received chemotherapy. Follow-up included annual bilateral mammograms and clinical breast examination every 3 to 6 months. Whereas 13 patients had intraoperative implantation of …


Oncolog, Volume 48, Number 06, June 2003, Dawn Chalaire, Sunni Hosemann, Kate O'Suilleabhain, Kerry L. Wright, Daniel J. Booser Md Jun 2003

Oncolog, Volume 48, Number 06, June 2003, Dawn Chalaire, Sunni Hosemann, Kate O'Suilleabhain, Kerry L. Wright, Daniel J. Booser Md

OncoLog MD Anderson's Report to Physicians (All issues)

  • Largest-Ever NCI Trial to Study Lung Cancer Screening
  • “What Choices Do I Have?” Breast Reconstruction Book and CD-ROM Help Patients Make Complicated Decisions
  • House Call: Coping with the Adverse Effects of Cancer Treatment
  • New Proton Therapy Center to Deliver Radiation with Precision, Few Side Effects
  • DiaLog: Treating Breast Cancer with Hormone Therapy: Past, Present, and Future, by Daniel J. Booser, MD, FRCPC, Associate Professor, Department of Breast Medical Oncology


Continued Cigarette Smoking By Patients Receiving Concurrent Chemoradiotherapy For Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival, Gregory Videtic, Larry Stitt, A. Dar, Walter Kocha, Anna Tomiak, Pauline Truong, Mark Vincent, Edward Yu Apr 2003

Continued Cigarette Smoking By Patients Receiving Concurrent Chemoradiotherapy For Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival, Gregory Videtic, Larry Stitt, A. Dar, Walter Kocha, Anna Tomiak, Pauline Truong, Mark Vincent, Edward Yu

Edward Yu

PURPOSE: To determine the impact of continued smoking by patients receiving chemotherapy (CHT) and radiotherapy (RT) for limited-stage small-cell lung cancer (LSCLC) on toxicity and survival. PATIENTS AND METHODS: A retrospective review was carried out on 215 patients with LSCLC treated between 1989 and 1999. Treatment consisted of six cycles of alternating cyclophosphamide, doxorubicin, vincristine and etoposide, cisplatin (EP). Thoracic RT was concurrent with EP (cycle 2 or 3) only. Patients were known smokers, with their smoking status recorded at the start of chemoradiotherapy (CHT/RT). RT interruption during concurrent CHT/RT was used as the marker for treatment toxicity. RESULTS: Of …